What Neuralink has accomplished so far

Neuralink Accomplishments & Current Status - Neuralink's N1 device, a wireless high-bandwidth brain-computer interface (BCI), is being used by at least 13 human patients [2] - Trial participants have accumulated over 15,000 hours of independent use of the BCI at home [2] - Patients are averaging around 50 hours per week of BCI usage, with peak usage exceeding 100 hours per week in some cases [7] - Neuralink received FDA approval for human trials in 2023, focusing on patients with paralysis and ALS [5] - The company has solved the thread retraction problem by updating brain signal decoding algorithms and shallower thread insertion [12] Expansion & Regulatory Approvals - Neuralink is now conducting studies in four countries: the United States, Canada, the UK, and the UAE [13][14] - International trials are a crucial step toward market readiness for treating paralysis, blindness, and other conditions [15] Future Products & Research - Neuralink plans to launch a thought-to-speech clinical trial in the US for patients who have lost the ability to speak [22] - Blind sight technology is expected to reach human trials next year, aiming to restore basic navigation and eventually full vision [25] - Neuralink is exploring hearing restoration and accessing deeper brain regions for helping with pain, mood, and memory regulation [26] - The company expects to work on helping with epilepsy and tinnitus in 2028 [27] Scaling & Technology - Engineers are working to increase electrode count from 1,000 channels to 10,000 and then 25,000 and beyond [28] - Neuralink aims to perform thousands of surgeries every month using the R1 surgical robot and dedicated clinics [29]